» Articles » PMID: 28751444

Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2017 Jul 29
PMID 28751444
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Trebananib is a first-in-class antiangiogenic peptibody (peptide-Fc fusion protein) that inhibits Angiopoietin 1 and 2. A pediatric phase 1 trial was performed to define trebananib dose-limiting toxicities (DLT), recommended phase 2 dose (RP2D), and pharmacokinetics (PK). Trebananib was administered by weekly infusion. Three dose levels (10, 15, or 30 mg/kg/dose) were evaluated using a rolling-six design. Part 2 evaluated a cohort of subjects with primary central nervous system (CNS) tumors. Pharmacokinetic sampling and analysis of peripheral blood biomarkers was performed during the first 4 weeks. Response was evaluated after 8 weeks. Correlative studies included angiogenic protein expression and DCE-MRI. Thirty-seven subjects were enrolled (31 evaluable for toxicity) with median age 12 years (range, 2 to 21). Two of 19 evaluable non-CNS subjects developed DLT at the 30 mg/kg dose level, including venous thrombosis and pleural effusion. In the CNS cohort, 3/12 subjects developed DLT, including decreased platelet count, transient ischemic attack, and cerebral edema with headache and hydrocephalus. Other grade 3 or 4 toxicities included lymphopenia ( = 4), anemia, thrombocytopenia, neutropenia, vomiting, and hypertension ( = 1 each). Response included stable disease in 7 subjects, no partial or complete responses. Two subjects continued study treatment with prolonged stable disease for 18 cycles (neuroblastoma) and 26 cycles (anaplastic astrocytoma). Pharmacokinetics appeared linear over 3 dose levels. Correlative studies demonstrated increased PlGF and sVCAM-1, but no change in endoglin or perfusion by DCE-MRI. Trebananib was well tolerated in pediatric patients with recurrent or refractory solid or CNS tumors. RP2D is 30 mg/kg. .

Citing Articles

Safety of Anti-Angiogenic Drugs in Pediatric Patients with Solid Tumors: A Systematic Review and Meta-Analysis.

Spini A, Ciccone V, Rosellini P, Ziche M, Lucenteforte E, Salvo F Cancers (Basel). 2022; 14(21).

PMID: 36358734 PMC: 9654149. DOI: 10.3390/cancers14215315.


Angiogenesis and Anti-Angiogenic Treatment in Prostate Cancer: Mechanisms of Action and Molecular Targets.

Ioannidou E, Moschetta M, Shah S, Parker J, Ozturk M, Pappas-Gogos G Int J Mol Sci. 2021; 22(18).

PMID: 34576107 PMC: 8472415. DOI: 10.3390/ijms22189926.


Use of Antiangiogenic Therapies in Pediatric Solid Tumors.

Ollauri-Ibanez C, Astigarraga I Cancers (Basel). 2021; 13(2).

PMID: 33445470 PMC: 7827326. DOI: 10.3390/cancers13020253.


Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma.

Carmagnani Pestana R, Hassan M, Abdel-Wahab R, Abugabal Y, Girard L, Li D Oncotarget. 2019; 9(102):37721-37732.

PMID: 30701027 PMC: 6340869. DOI: 10.18632/oncotarget.26507.

References
1.
Wu B, Lewis L, Harvey R, Rasmussen E, Gamelin E, Sun Y . A Pharmacokinetic and Safety Study of Trebananib, an Fc-Fusion Peptibody, in Patients With Advanced Solid Tumors and Varying Degrees of Renal Dysfunction. Clin Pharmacol Ther. 2017; 102(2):313-320. DOI: 10.1002/cpt.617. View

2.
Goede V, Coutelle O, Neuneier J, Reinacher-Schick A, Schnell R, Koslowsky T . Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer. 2010; 103(9):1407-14. PMC: 2990609. DOI: 10.1038/sj.bjc.6605925. View

3.
Lu J, Rasmussen E, Karlan B, Vergote I, Navale L, Kuchimanchi M . Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection. Cancer Chemother Pharmacol. 2012; 69(5):1135-44. PMC: 3337406. DOI: 10.1007/s00280-011-1787-5. View

4.
Karlan B, Oza A, Richardson G, Provencher D, Hansen V, Buck M . Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol. 2011; 30(4):362-71. DOI: 10.1200/JCO.2010.34.3178. View

5.
Herbst R, Hong D, Chap L, Kurzrock R, Jackson E, Silverman J . Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol. 2009; 27(21):3557-65. DOI: 10.1200/JCO.2008.19.6683. View